Iovance Biotherapeutics, Inc. (IOVA) Income Statement

The 65.7% YoY growth in 2026Q2, up from 44.8% in the prior quarter, indicates accelerating commercial adoption of lifileucel. However, the absolute revenue base of $99.3M in a quarter is still small, and the one-and-done nature of the therapy suggests growth will depend on expanding patient referrals and ATC onboarding. The trajectory appears robust but may face lumpiness as manufacturing and infusion capacity scale.

The reported 97.23% TTM gross margin is an outlier for autologous cell therapy, likely due to non-recurring items or timing of COGS recognition. As commercial volumes scale, the labor-intensive, patient-specific manufacturing process is expected to compress margins toward more realistic levels, as evidenced by the 54.6% in 2026Q2. Investors should monitor whether the company can achieve sustainable gross margins above 50% as it automates production.

While revenue growth has outpaced expense growth, the absolute operating loss of $51.9M in 2026Q2 remains substantial. R&D expenses have stayed relatively flat around $60-80M per quarter, while SG&A has been volatile, with 2026Q2 showing zero SG&A, which may be a data artifact. The path to operating profitability requires significant revenue scaling to absorb the fixed manufacturing and commercial infrastructure costs.

The increase in COGS from $1.0M in 2026Q1 to $45.1M in 2026Q2 suggests that the company is now recognizing the full cost of producing lifileucel for commercial patients. R&D spending is still high, indicating ongoing investment in clinical trials for label expansion. The company's expense discipline appears focused on scaling manufacturing, but the lack of SG&A in 2026Q2 is unusual and may warrant clarification.

The approval of lifileucel for metastatic melanoma was the pivotal event that enabled the revenue inflection, as evidenced by the sequential growth from 2024Q1 to 2024Q2. The integration of Proleukin into the portfolio further supports the commercial model by controlling a key component of the treatment regimen. This inflection has lasting impacts, as the company now has a validated platform for solid tumors, but it also brings the challenges of scaling a complex autologous therapy.